Novartis Raises Guidance After Trial Setbacks Hit Profit
Novartis raised its 2026 earnings guidance, expecting low single-digit growth, up from a previous forecast of a decline. Q3 sales rose 4% to $14.52B, but net profit fell to $1.20B from $3.93B due to a $1.9B write-down on a failed drug trial. Core operating profit rose 10% at constant currency, beating analyst estimates of $5.61B.
How this was made
The 30-second read
Why it matters
The guidance upgrade is likely to drive short‑term buying pressure, while the write‑down highlights execution risk in the pipeline.
Market read
First‑time guidance lift for a large‑cap pharma, material for traders and investors.
What to watch
Currency headwinds and upcoming patent expiries may temper long‑term upside.
Background
Novartis reported Q3 results with solid sales growth, a $1.9 bn write‑down on a neuromuscular candidate, and subsequently raised its 2026 core operating profit guidance.
Ticker impact
Novartis raised its full-year core operating profit guidance after reporting a Q3 profit beat and a $1.9 bn write‑down, marking the first disclosure of the new guidance.
likely upward pressure as investors price in higher profit expectations
The guidance lift is a fresh, material fact for a large‑cap pharma, and the beat on core profit exceeds consensus, prompting buying interest.
Market effects
May lift sentiment for the broader pharma sector as peers are re‑rated on higher growth expectations.
European markets could see a modest rally in healthcare stocks.
Guidance lift from a top global drugmaker can influence global biotech indices.
Counterpoint
The $1.9 bn write‑down could signal deeper pipeline challenges, suggesting caution.
Key entities
- companyNovartis
Swiss multinational pharmaceutical firm.
